BBO-11818 monotherapy demonstrated a confirmed partial response (PR) in pancreatic cancer and anti-tumor activity was observed across dose levels and tumor types with tumor reductions at higher dose ...

For the first time ever, the board that disciplines attorneys is recommending a former Massachusetts prosecutor lose her law license for failing to turn over evidence that might have exonerated ...

SOUTH SAN FRANCISCO, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway ...

BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics targeting renin-angiotensin system and phosphoinositide ...

- The first patient has been dosed in the ONKORAS-101 trial for the study of BBO-8520 in adult subjects with KRAS G12C non-small cell lung cancer - BBO-8520 is a first-in-class orally bioavailable and ...

Beta-Barium Borate (BBO) is a nonlinear crystal characterised by a broad phase-matchable range from 409.6nm to 3500nm, a wide transmission region from 190nm to 3500nm and a high laser damage threshold ...

PALO ALTO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and ...

Ultrathin BBO crystals of thickness down to 10 microns with protective hard (IBS) AR coating are available. EKSMA OPTICS offers BBO crystals of thickness down to 10 microns for frequency conversion of ...

BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in patients with KRAS mutant pancreatic, non-small cell lung, and colorectal cancer with initial Phase 1 clinical data expected ...